Premium
Treatment of MEK inhibitor‐induced paronychia with doxycycline
Author(s) -
Sun Qisi,
Antaya Richard J.
Publication year - 2020
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14276
Subject(s) - doxycycline , selumetinib , medicine , paronychia , neurofibromatosis , dermatology , dosing , neurofibroma , antibiotics , surgery , pathology , cancer , colorectal cancer , microbiology and biotechnology , kras , biology
Abstract A 12‐year‐old girl with neurofibromatosis type 1 and a large facial plexiform neurofibroma had been participating in a selumetinib clinical trial for the past 5 years. Despite decreased tumor size, she developed recalcitrant selumetinib‐induced paronychia. Various antibiotics, topical medications, and surgeries were only minimally effective. Full‐dose doxycycline resolved the paronychia, and sub‐antimicrobial dosing has prevented recurrences for several months, permitting her to continue her selumetinib course.